ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Options Flow

Live Options Flow

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
S&P TSX Capped Composite...
39.97
0.10%
US Tech 100
20,029.20
-0.54%
S&P 500
5,917.11
0.00%
US Dollar vs CAD
1.39745
0.03%
Bitcoin
97,155.29
2.96%
Registration Strip Icon for pro Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. USOTC

  6. Elite Pharmaceuticals Inc (QB) (ELTP) Share Price

Elite Pharmaceuticals Inc (QB)

Elite Pharmaceuticals Inc (QB) (ELTP)

USOTC
0.6635
-0.0115
(-1.70%)
Closed November 21 3:00PM
Delayed by 15 minutes

Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

Premium

Key stats and details

Current Price
0.6635
Bid
0.651
Ask
0.667
Volume
1,534,474
0.627 Day's Range 0.70
0.1213 52 Week Range 0.7598
Market Cap
708.799M
Previous Close
0.675
Open
0.685
Last Trade
8323
@
0.6635
Last Trade Time
Financial Volume
US$ 1,027,575
VWAP
0.669659
Average Volume (3m)
3,659,362
Shares Outstanding
1,068,273,108
Dividend Yield
-
PE Ratio
35.11
Earnings Per Share (EPS)
0.02
Revenue
56.63M
Net Profit
20.11M

About Elite Pharmaceuticals Inc (QB)

Elite Pharmaceuticals, Inc. is a specialty pharmaceutical company that develops niche generic products. Elite specializes in developing and manufacturing oral, controlled-release drug products. Elite owns multiple generic products which have been licensed to Lannett Company, Prasco, LLC, Epic Pharma... Elite Pharmaceuticals, Inc. is a specialty pharmaceutical company that develops niche generic products. Elite specializes in developing and manufacturing oral, controlled-release drug products. Elite owns multiple generic products which have been licensed to Lannett Company, Prasco, LLC, Epic Pharma, LLC, and TAGI Pharma. Elite operates a cGMP and DEA registered facility for research, development, and manufacturing located in Northvale, NJ. For more information, visit www.elitepharma.com. Show more

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Website
www.elitepharma.com
Headquarters
Carson City, Nevada, USA
Founded
-
Elite Pharmaceuticals Inc (QB) is listed in the Pharmaceutical Preparations sector of the OTCMarkets with ticker ELTP. The last closing price for Elite Pharmaceuticals (QB) was US$0.68. Over the last year, Elite Pharmaceuticals (QB) shares have traded in a share price range of US$ 0.1213 to US$ 0.7598.

Elite Pharmaceuticals (QB) currently has 1,068,273,108 shares outstanding. The market capitalization of Elite Pharmaceuticals (QB) is US$721.08 million. Elite Pharmaceuticals (QB) has a price to earnings ratio (PE ratio) of 35.11.

Ask ADVFN Intelligence (AI)

ELTP Latest News

More News

Form 8-K - Current report

November 18 2024
Edgar (US Regulatory)

Form 8-K - Current report

November 14 2024
Edgar (US Regulatory)

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

November 14 2024
Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities

October 28 2024
Edgar (US Regulatory)

Form 144 - Report of proposed sale of securities

October 23 2024
Edgar (US Regulatory)

ZenaTech, Inc. (NASDAQ: ZENA) Software Company Acquisition

ZenaTech, Inc. (NASDAQ: ZENA) Software Company Acquisition     Miami, FL – October 23, 2024 -- InvestorsHub NewsWire – EmergingGrowth.com, a leading...

October 23 2024
InvestorsHub NewsWire

Form 8-K - Current report

October 10 2024
Edgar (US Regulatory)

Form 8-K - Current report

August 27 2024
Edgar (US Regulatory)

Form 8-K - Current report

August 14 2024
Edgar (US Regulatory)

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

August 14 2024
Edgar (US Regulatory)
PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
10.093516.40350877190.570.720.4842269870.60786659CS
40.05599.200131665570.60760.720.432134661130.53164122CS
120.4045156.1776061780.2590.75980.245736593620.47222268CS
260.5145345.3020134230.1490.75980.14521341610.41385748CS
520.511335.0819672130.15250.75980.121316411550.32796264CS
1560.62771753.351955310.03580.75980.0239592680.21338163CS
2600.575649.7175141240.08850.75980.0239674570.15321477CS

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
EGRNFChina Evergrande Group (CE)
US$ 0.0102
(1,019,900.00%)
900
WRCDFWirecard AG (CE)
US$ 0.01
(999,900.00%)
350
CCTLCoin Citadel (PK)
US$ 0.0002
(19,900.00%)
1.28M
RDVARDVA Inc (CE)
US$ 0.0002
(19,900.00%)
10k
AGRDFMinnova Corporation (PK)
US$ 0.0101
(10,000.00%)
10k
ISUNQiSun Inc (CE)
US$ 0.000001
(-99.86%)
12.5k
YAYOYayYo Inc (CE)
US$ 0.000001
(-99.80%)
44.61k
GBCHFMetaverse Capital Corporation (CE)
US$ 0.000001
(-99.00%)
200
NTRRNeutra Corporation (CE)
US$ 0.000001
(-99.00%)
40k
BTTXBetter Therapeutics Inc (CE)
US$ 0.000001
(-99.00%)
60.2k
THBDThird Bench Inc (PK)
US$ 0.0001
(0.00%)
183.32M
RDARRaadr Inc (PK)
US$ 0.0006
(-25.00%)
131.72M
BDPTBioadaptives Inc (PK)
US$ 0.0001
(-50.00%)
121.82M
GRLFGreen Leaf Innovations Inc (PK)
US$ 0.0001
(0.00%)
111.8M
AITXArtificial Intelligence Technology Solutions Inc (PK)
US$ 0.003
(-14.29%)
97.54M

ELTP Discussion

View Posts
kayak_wench kayak_wench 2 hours ago
The last BE study PR we got was on Aug 28, 2023 for Vyvanse (during Q2 2024).
From Q3 2024 (starting at Q3 because I can't know if any of Q2 was for Vyvanse studies) forward Elite has spent a total of $7.2M on research and development. Sure would be nice to get another BE or two up to the plate as it can take over a year to get a newly approved BE to market. The first half of calendar year 2025 will be on growing markets of new products, but I expect we will be topping out by end of summer (with that period being reported in Nov 2025). Of course Purdue could give up sometime in the year and that would definitely give us more fuel to continue growth.

Research and development expenses since Vyvanse's successful BE
Q3 2024 1.4M
Q4 2024 6.9M - (1.1M+2.6M+1.4M) = 1.8M
Q1 2025 2.1M
Q2 2025 1.9M
👍️0
kayak_wench kayak_wench 2 hours ago
I don't agree that the $0.60 is the value the market gave t use for our current drug line. I believe at $0.60 the market was starting to price in the Vyvance because we didn't hit that until Nov 18th during the conference call. The price was consolidating to the low 0.51 to 0.52 range (ringing up and down to get there of course) until a few minutes into the conference call when it became evident that the Carter and Nasrat were in good moods. It was during that call we learned everything was still going fine. So you are missing a dime off the impact of Vyvance....and that is the impact so far. Remember the mid-Aug call when Nasrat told us of the continuous wave of new products. The market didn't really price that in for a couple of weeks.
👍️0
HGilS HGilS 4 hours ago
Me 2.
👍️0
Destiny Defined Destiny Defined 4 hours ago
I love the guy, and think he's done a great job. His intelligence, and sense of humor are top tier. The MEGA stuff had me dying. 😆
👍️ 2
HGilS HGilS 4 hours ago
You bet he is.
👍️0
NASDAQ2020 NASDAQ2020 4 hours ago
Is IB still on the MB ?
👍️0
Destiny Defined Destiny Defined 4 hours ago
I was poking fun of the stupid bashers calling him that...tied in with a play on, "Can you smell what the Rock is cooking?" As in...Nasrat has a plan and is executing it very well. If anyone is too daft to either already have or decide to now take a seat at his table, their loss. I've been a long since 2009, dude. Check out my posting history. I knew N2k personally. So....
👍️ 3
HGilS HGilS 5 hours ago
I can’t stand people calling the ceo the rat. Destiny is ib_
👍️0
HGilS HGilS 5 hours ago
No we don’t. what are you cooking destiny defined?
👍️0
NASDAQ2020 NASDAQ2020 5 hours ago
Correction:
1/2 ownership of the profit split of Adderalls ($2B market) = $0.60

Full ownership of Vyvance ($4.3B) = $0.06 more

Todays price $$0.66

Forward lookin’ Market was well aware that Vyvance was definitely going to get approval first time around due to Nasrats awesome track record with ANDA approvals.
👍️0
Destiny Defined Destiny Defined 5 hours ago
Seed has been planted. Harvest will be here in due time. Our little farma gonna be growing all sorts of greenery for us to feast upon. My seat at the table has already been secured. Can you smell what the "Rat" is cooking? Lol....
👍 1
HGilS HGilS 5 hours ago
2 big catalysts by year end. This should fix it.
🎓️ 1 👍️ 1
NASDAQ2020 NASDAQ2020 5 hours ago
Vyvance in extreme shortage has the potential to take a more significant market share since its API supplier is different than all the other competitors .
10-15-20% potentially of a $4.3 B market.
Today’s forward looking Value factored in = $0.06 since approval.
👍️ 2
jour_trader jour_trader 5 hours ago
It's half ownership of the profit split, not the mfg revenue. 
🤪 1
NASDAQ2020 NASDAQ2020 5 hours ago
1/2 ownership of Adderalls ($2B market) = $0.60

Full ownership of Vyvance ($4.3B) = $0.06 more

Todays price $$0.66
👍️0
Destiny Defined Destiny Defined 6 hours ago
C'mon, man. Reality ain't no fun. 🤪
👍️0
jour_trader jour_trader 6 hours ago
Companies present non-GAAP metrics all of the time. They have a separate deck and this is what they walk through - results, comparisons, key metrics, forecast, etc. 

You don't exclude it from GAAP reporting to SEC, but you most certainly can report it in a PR and during cc when reviewing financials.
👍️0
jour_trader jour_trader 6 hours ago
How could they buy 500M shares without spiking the share price?  I don't think that is realistic. 
👍️0
VortexAstronaut781 VortexAstronaut781 6 hours ago
Not just reddit but some folks here too. Yes I would love to see this stock go higher too, doesn't mean every negative price action is result of so called manipulation....
👍 1
DividendGamer DividendGamer 7 hours ago
Really hate to see all these claims of manipulation on reddit about Wall Street boogeymen "manipulators", so sick of all this GME MOASS nonsense on every stock forum like reddit etc. Thinner markets have lower volume and broader swings, it is as simple as that. OTC are pretty much as thin as they get aside from private share groups. I have stock in OTC companies that I can easily see each of my trades when less than 1k trade a day. Some of them are so thinly traded the ticker doesn't even make the correct tape updates because of the minimum update thresholds. There is no conspiracy, just big versus small markets.
👍️ 3
Trend-Setter Trend-Setter 7 hours ago
A poster on YMB is impersonating Pharma Sleuth. If you check the posting history, you'll figure out who that person is.
👍️ 2 🙄 1 🤔 1
aBeezlee aBeezlee 7 hours ago
I get the impression this will spike by EOM. Waiting for my transfer to complete, hopefully by Friday.
👍️ 1 🙄 1
Son of Tangerine Son of Tangerine 8 hours ago
Clearly AI written too. Ever wonder how much money they get on clicks from that stuff? Is it like automated mad libs? So much AI content out there right now. How long you think it takes to generate each article?

I think they did do one that wasn't AI.
👍 3 🙄 1
jour_trader jour_trader 8 hours ago
Yes, lol. Zack's published quite the number for the financially illiterate.
🎓️ 1 👍️ 1
Son of Tangerine Son of Tangerine 8 hours ago
Dear lord, please don't let the stock price go up so the P&L looks better when we calculate the increasing derivative value due to the stock going up and the company having massive growth?
👍️ 4 😂 5
Son of Tangerine Son of Tangerine 8 hours ago
For the completely ignorant ?
👍️ 2
Son of Tangerine Son of Tangerine 8 hours ago
If you sold and are trying to buy your shares back, just say it. You have been spouting nonsense since the stock was .03. Anyone that listened ..well...shouldn't have and shouldn't ever.
👍️ 8 💯 4
jour_trader jour_trader 8 hours ago
It's all optics
👍️0
Son of Tangerine Son of Tangerine 8 hours ago
Huh? You give a crap about derivatives because the stock went up? You like having bigger P&L when the stock goes down? No one gives a crap about derivatives in determining the value of a company.
👍️ 4
csuck555 csuck555 8 hours ago
Everyone here should be putting their entire net worth into this at these prices! 
Utter embarrassment that we're not over $1.00 already.  
🎓️ 1 👍️ 4 💯 3
NASDAQ2020 NASDAQ2020 8 hours ago
What was priced in at $0.75 ?

Probably was high so to take out more stop losses
TIA
👧 1 👶 1
NASDAQ2020 NASDAQ2020 8 hours ago
I think he left at $0.15.
👍️0
jour_trader jour_trader 8 hours ago
From a P&L standpoint, we may have a bigger loss next Q due to warrants. Share price has surged since end of last fiscal Q. Even with a large increase in rev, I don't think this will solve for the accounting of the warrants. This will be a noose around our neck from P&L optics standpoint. 

The reason warrants are recorded as a liability because it shows the fair value loss the company is realizing during the fiscal period by issuing shares at current share price vs the warrant strike price.  It's the amount Elite is out of the money  
on as a gift to Nasrat.
👍️0
The ELTP King The ELTP King 9 hours ago
Market is forward looking.

Vyvanse is priced in and so are all the upcoming ANDA launches.

Need a positive BE study if we want the PPS to rise more.

Nasrat said AT LEAST two filings by the end of 2024. (HE LIED. WE WON'T RECEIVE ANY)
❓️ 1
The ELTP King The ELTP King 9 hours ago
Do you know how many people submitted questions and/or threatened Nasrat with legal action about Mikah this last CC?

Wonder if WeeZuhl raised HELL about this?

I think the issue is MIKAH
👍️0
VortexAstronaut781 VortexAstronaut781 9 hours ago
This is way less pullback than I anticipated, hopefully we get whales buy in and form new support over next week
👍️ 3
BoyWidaDreamOr2 BoyWidaDreamOr2 9 hours ago
Jammy!!! Why do you do this???

P.S. please remove my 1 post/day limit thxxx
👍️0
IB_ IB_ 10 hours ago
Almost ........... $0.70 was close !!!!!!!!!!!!!!!!!!!!!!!!!

IB_🤴
👍️0
Cake Eater Cake Eater 10 hours ago
I'll call Joaquin Duato, the current Chairman and Chief Executive Officer of Johnson & Johnson and get things rolling.
He may "LOVE IT" also 🤷‍♂️😂
👍 1 🤣 1
Cake Eater Cake Eater 10 hours ago
Next you will be using this RD line:

"I was so poor, my rich aunt died; in the will, I owed her $20."
👍️0
sharkey1 sharkey1 11 hours ago
Lets remember how to use the force as we live our daily lives



you can do this
👍 1
DividendGamer DividendGamer 11 hours ago
Tell everyone you know to tell 10 people to buy $100+ we can start a new MOASS like GME


👍️ 2
jammy32 jammy32 11 hours ago
I think the issue is MIKAH
👎️ 1 😡 1
sharkey1 sharkey1 11 hours ago
❓️ 1
sharkey1 sharkey1 11 hours ago
👍️ 1 ❓️ 1
sharkey1 sharkey1 11 hours ago
👍️ 1 ❓️ 1
sharkey1 sharkey1 11 hours ago
Hey

❓️ 1
rocioyogi rocioyogi 11 hours ago
Sorry, been here since 2014 but this is total total BSBBS how do you get this strong approved and they’re playing with it like just no respect no respect worse than Rodney Dangerfield no respect. Oh well I know where we will end up in the future Sorry, been here since 2014 but this is total total BSBBS how do you get this strong approved and they’re playing with it like just no respect no respect worse than Rodney Dangerfield no respect. Oh well I know where we will end up in the near near future, but this is total BS!!!!
👍️ 3
rocioyogi rocioyogi 12 hours ago
Lv it!!! I’m with you on this one that would be tremendous. Love it stock and dividend. Love it. Love it love it.
👍️ 1
sharkey1 sharkey1 12 hours ago
Well thank you very much, we can do this
It's monopoly money to those people

could you imagine each one of your shares to be 160 bucks each
👍️0

Your Recent History

USOTC
ELTP
Elite Pharmaceuticals (QB)
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Canada
Company
Business
Popular
Get The App
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved